ClinicalTrials.gg
CompletedNCT03802201TRANSCENDUpdated Jul 16, 2021

Study of PTG-300 in Non-Transfusion Dependent and Transfusion-Dependent Beta-Thalassemia Subjects With Chronic Anemia

A Phase 2 interventional study of PTG-300 in β-thalassemia, Ineffective Erythropoiesis and Chronic Anemia, sponsored by Protagonist Therapeutics, Inc.. Completed at 33 sites in 9 countries. Open to participants aged 12 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-07-16.

Primary conditionThalassemiaRegistry: AnemiaReclassifiedWhy we changed it
Registry
Anemia — the first condition term the registry derived for this study.
ClinicalTrials.gg
Thalassemia
Why
  1. The study's listed conditions name Thalassemia, a narrower term within Anemia.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Protagonist Therapeutics, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jul 2020, 6 years 3 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Jul 2021.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
63
Allocation
Not applicable
Ages
12 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 20 studies in Thalassemia with a site in Turkey — 2 open to participants now, 5 under way, 3 of them phase 3. Thalassemia · Turkey.

Enrollment
13th of 20
63 · median 128
Started
2018
with 1 other
Phase 2
8 of 20
none open now
Registered
12th of 20
by date
Lead sponsor
2 of 20
Protagonist Therapeutics, Inc.

Among the 20 studies in Thalassemia with a site in Turkey, this one is the 13th largest by enrollment, is one of 2 that started in 2018, is one of 8 in phase 2, and was the 12th registered.

Thalassemia

250 studies on the registry are indexed under Thalassemia; 43 are open to participants now.

Browse Thalassemia studies →

Open to participants now

2 of the 20 studies in Thalassemia with a site in Turkey are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 28 Thalassemia studies recruiting now, 7 (25%) set no upper age limit and 18 (64%) stop at 75 or younger; 22 take children under 18; none take healthy volunteers.

This study: 12 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Thalassemia with a site in Turkey, or all of them as a file.
02

Study summary

This is a Phase 2 open-label, single-arm design study with dose escalation by subject cohort . The study is designed to monitor the PTG-300 safety profile, to obtain preliminary evidence of efficacy of PTG-300 for the treatment in β-thalassemia.

Read the detailed description

This is a Phase 2 open-label, single-arm design study with dose escalation by subject cohort and with the potential for individual titration (dose increase or decrease) within each cohort. The study is designed to monitor the PTG-300 safety profile, to obtain preliminary evidence of efficacy of PTG-300 for the treatment of chronic anemia in β-thalassemia and to evaluate the appropriate dosing regimen for PTG-300 in the target population

03

Conditions studied

  • β-thalassemia
  • Ineffective Erythropoiesis
  • Chronic Anemia

Browse trials for

Keywords

  • chronic anemia
  • β-thalassemia
04

In context

Thalassemia Reclassified

250 studies on the registry are indexed under Thalassemia; 43 are open to participants now.

This study's enrollment of 63 is above the median of 33 across 170 interventional studies indexed under Thalassemia.

Browse Thalassemia studies →

Lead sponsor

Protagonist Therapeutics, Inc. is the lead sponsor of 13 studies on the registry; none are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 1 (11%) have results posted.

Compared within Thalassemia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Anemia. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
12 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  1. Male and female subjects aged 18 to 65 years, inclusive (Cohorts 1-4b).
  2. Male and female subjects aged 12-\<18 years, with a minimum weight of 30 kg (Cohorts 5 and 6).
  3. Documented diagnosis of β-thalassemia with no other abnormality.

Inclusion criteria applicable only for NTD β-thalassemia subjects:

  1. Mean Hgb \< 10.0 g/dL of two measurements (one performed 7-28 days prior to dosing and the other performed within 7 days prior to dosing).
  2. Requirement of \< 6 units RBC transfusion in a 24 week period with the last transfusion at least 8 weeks before screening.

Inclusion criteria applicable only for TD β-thalassemia subjects:

  1. Transfusion requirement of at least 6 units of RBC in the 24 weeks prior to screening with no transfusion free period > 45 days.
  2. Last RBC transfusion 5-10 days prior to dosing.

Main Exclusion Criteria:

  1. Subjects with Sickle Cell disease, Hgb H, Hb Bart's hydrops foetalis or hemoglobin S
  2. Infection requiring hospitalization or IV antimicrobial therapy, or opportunistic infection within 6 months of dosing, any infection requiring antimicrobial therapy within 2 weeks of dosing; history of infection with (HIV).
  3. Subject has a concurrent , unstable or uncontrolled cardiovascular, pulmonary, hepatic, renal, gastrointestinal, genitourinary, hematological, coagulation, immunological, endocrine/metabolic or other medical disorder that, in the opinion of the Investigator, might confound the results of the study or pose additional risk to the subject by their participation in the study.
  4. Known primary or secondary immunodeficiency.
  5. History within 6 months of screening of any of the following:

    myocardial infarction, unstable angina, , decompensated heart failure requiring hospitalization, congestive heart failure ( Class 3 or 4), uncontrolled arrhythmias, cardiac revascularization, stroke, uncontrolled hypertension (resting systolic blood pressure [BP] > 160mmHg or resting diastolic BP > 100mmHg on more than one occasion) or uncontrolled diabetes (Hgb A1c > 9% or > one episode of severe hypoglycemia).

  6. Pregnant or lactating females.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
63 participants (actual)

Study arms

  • Experimental
    PTG-300 Active

    Drug: PTG-300 Subcutaneous

    Drug: PTG-300

Interventions

07

What researchers measure

Primary outcomes

  1. NTD: Proportion of responders at each dose

    NTD subjects who achieve an increase in Hgb without transfusion

    Time frame: 4 week period

  2. TD: Proportion of clinical responders at each dose

    TD subjects who achieve a reduction in red blood cell (RBC) units required over an 8 week period

    Time frame: 8 week period

08

Study locations

33 sites
  • UCSF Benioff Children's Hospital
    Oakland, California 94609, United States
  • Boston Children's Hospital
    Boston, Massachusetts 02115, United States
  • Hospital of The University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • University General Hospital of Patras
    Patras, Achaia, Greece
  • Laiko General Hospital of Athens
    Athens, Attiki 11562, Greece
  • Athens General Hospital 'G Gennimatas'
    Athens, Attiki, Greece
  • Hippokration Hospital
    Thessaloníki, Greece
  • Presidio Ospedaliero Antonio Perrino
    Brindisi, 72100, Italy
  • Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
    Milano, 20122, Italy
  • AOU dell'Università degli Studi della Campania Luigi Vanvitelli
    Napoli, 80138, Italy
  • Chronic Care Center
    Beirut, Lebanon
  • Hospital Ampang
    Ampang, 68000, Malaysia
  • Hospital Pulau Pinang
    George Town, 10990, Malaysia
  • Hospital Sultanah Aminah
    Johor Bahru, 80100, Malaysia
  • Queen Elizabeth Hospital
    Kota Kinabalu, 88586, Malaysia
  • Hospital Umum Sarawak
    Kuching, 93586, Malaysia
  • Chulalongkorn University
    Bangkok, 10330, Thailand
  • Siriraj Hospital Mahidol University
    Bangkok, 10700, Thailand
  • Maharaj Nakorn Chiang Mai Chiang Mai University
    Chiang Mai, 50200, Thailand
  • Khon Kaen University
    Khon Kaen, 40002, Thailand
  • Naresuan University
    Phitsanulok, 65000, Thailand
  • University Hospital Farhat Hached
    Sousse, 4000, Tunisia
  • Bone Marrow Transplant Center
    Tunis, 1006, Tunisia
  • Aziza Othmana Hospital
    Tunis, 1008, Tunisia
  • Principal Military Hospital
    Tunis, 1089, Tunisia
  • Acibadem Adana Hospital
    Adana, 01130, Turkey
  • Hacettepe University Medical Faculty
    Ankara, 06100, Turkey
  • Akdeniz Universitesi Hastanesi
    Antalya, 07059, Turkey
  • Istanbul Universitesi Istanbul Tip Fakultesi Hastanesi
    Istanbul, 34093, Turkey
  • Ege Universitesi Tip Fakultesi
    Izmir, 35100, Turkey
  • Mersin University Medical Facult
    Mersin, 33343, Turkey
  • Barts Health NHS Trust
    London, E1 1BB, United Kingdom
  • Barts Health NHS Trust
    London, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2018 to primary completion in Jul 2020, 19 months.

Of 25 phase 2 interventional studies under Thalassemia, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 67. This study's 19 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2019
First posted
Jan 14, 2019
StartActual
Dec 19, 2018
Primary completionActual
Jul 31, 2020
CompletionActual
Jul 31, 2020
Results delay requested
Jul 9, 2021
Last update
Jul 16, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03802201
Lead sponsor
Protagonist Therapeutics, Inc.
Responsible party
Sponsor
First posted
Jan 14, 2019
Start date
Dec 19, 2018
Primary completion
Jul 31, 2020
Completion
Jul 31, 2020
Last update
Jul 16, 2021

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rusfertide

Start the discussion